73798-61-5

Upstream product

• 51-17-2 benzoimidazole 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 589-17-3 p-bromobenzyl chloride 
• 2280-44-6 D-Glucose 
• 7191-86-8 N¹-(4-bromobenzyl)benzene-1,2-diamine 
• 95-54-5 1,2-diamino-benzene 

Downstream Products

• 575465-26-8 3-(4-benzimidazol-1-ylmethylphenyl)-5-isobutyl-N-tert-butylthiophene-2-sulfonamide 
• 461702-08-9 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]-1H-benzo[d]imidazole 
• 1204654-52-3 (4-((1H-benzo[d]imidazol-1-yl)methyl)phenyl)boronic acid 
• 1247725-83-2 4'-[(1H-benzimidazol-1-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-[1,1'-biphenyl]-2-sulfonamide 
• 1446853-40-2 1-(4-bromobenzyl)-3-(4-chlorobenzyl)benzimidazolium chloride 
• 1446853-43-5 1-(4-bromobenzyl)-3-(4-methylbenzyl)benzimidazolium bromide 
• 1446853-46-8 1-(4-bromobenzyl)-3-(2-phenylethyl)benzimidazolium bromide 
• 1446853-48-0 1-(4-bromobenzyl)-3-ethylbenzimidazolium iodide 
• 1610526-10-7 1-(4-bromobenzyl)-2-(diphenylphosphino)benzimidazole 
• 575465-27-9 3-(4-benzoimidazol-1-ylmethyl-phenyl)-5-isobutyl-thiophene-2-sulfonic acid amide 

Relevant academic research and scientific papers

Benzimidazolium salts prevent and disrupt methicillin-resistant: Staphylococcus aureus biofilms

Emergence of resistant bacteria encourages us to develop new antibiotics and strategies to compensate for the different mechanisms of resistance they acquire. One of the defense mechanisms of resistant bacteria is the formation of biofilms. Herein we show

Metal-Free Synthesis of Benzimidazoles via Oxidative Cyclization of d -Glucose with o-Phenylenediamines in Water

d-Glucose has been identified as an efficient C1 synthon in the synthesis of benzimidazoles from o-phenylenediamines via an oxidative cyclization strategy. Isotopic studies with 13C6-d-glucose and D2O unambiguously confirmed the source of methine. The notable features of this method include the following: broad functional group tolerance, a biorenewable methine source, excellent reaction yields, a short reaction time, water as an environmentally benign solvent, and the synthesis of vitamin B12 component on the gram scale.

A planar anthracene–imidazolium/anthracene–benzimidazolium cation system in a spherical polyoxometalate matrix: Synthesis, crystallography and spectroscopy

A series of ion–pair compounds, comprising of Lindqvist type isopolyanions viz., [Mo6O19]2?and [W6O19]2?as the counter anions and anthracene–imidazolium/anthracene–benzimidazolium as counter cations, have been described. Structures of the isolated stoichiometric solids have been unambiguously determined by single crystal X-ray diffraction analysis. In spite of the structural incompatibility between anthracene (planar) and the present polyoxometalate anions (spherical), coulombic and several intermolecular weak interactions, e.g. C–H?O, C–H?π, π–π, etc. compensate the destabilization energy raised due to presence of the structurally mis-matched components in the respective crystal lattices. Single-crystal- as well as powder X-ray-diffraction (PXRD) analyses reveal iso-structural relationship between the hexamolybdates- and hexatungstates-associated ion pair compounds. Conformational variation has been observed in the crystal structures containing benzyl benzimidazolium counter cations. Diffuse reflectance electronic absorption spectral studies are performed to understand the relatively intense color of the title compounds in their solid states in comparison to their respective solution states.

The synthesis of an anionic, tetraphenylborate-functionalized, [P,N]-hybrid phosphinobenzimidazole ligand and its hemilabile behaviour in ruthenium zwitterion chemistry

A new anionic [P,N]-hybrid ligand based on a phosphinobenzimidazole scaffold and functionalized with a tetraphenylborate substituent is reported. This new anionic ligand readily chelates to a variety of ruthenium- cyclopentadienyl and -pentamethylcyclopentadienyl precursors to form a series of zwitterionic ruthenium piano-stool complexes (η5-C 5R5)Ru(L)(κ2-P,N) (R = H or Me; L = CO or PPh3). In the presence of excess CO or 1-alkynes, the chelate complexes undergo ring-opening of the κ2-P,N ligand at the ruthenium-nitrogen bond (in some cases reversibly) under relatively mild conditions. In particular, the reactions with 1-alkynes proceed via vinylidene intermediates which subsequently insert into the ruthenium-nitrogen bond of the κ2-P,N ligand.

Synthesis and biological evaluation of 4′-[(benzimidazole-1-yl) methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists

A series of 4′-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives (Ia-Il) were synthesized and biologically evaluated. It was found that Ig, the most active compound, antagonized both Ang II AT1 and endothelin ETA receptors (AT1 IC50 = 8.5, ETA IC50 = 8.9 nM), and was more potent than losartan in RHRs with no significant effect on heart rate. The preliminary structure-activity relationships were also discussed in the present paper.

METHODS FOR THE PREPARATION OF AZOLE COMPOUNDS

The present invention is directed to processes, compositions and methods associated with the preparation of azole derivatives of formula I:

AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS

The present invention provides a compound of formula I: and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.

Pyrazolopyrimidines as therapeutic agents

The present invention is directed to pyrazolopyrimidine derivatives of formula (I) wherein the substituents are defined herein, which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.

Design, synthesis, and biological evaluation, of the first selective nonpeptide AT2 receptor agonist

The first druglike selective angiotensin II AT2 receptor agonist (21) with a Ki value of 0.4 nM for the AT2 receptor and a Ki > 10 μM for the AT1 receptor is reported. Compound 21, with a bioavailability of 20-3

Pyrazolopyrimidines as therapeutic agents

The present invention provides compounds of Formula I, including pharmaceutically acceptable salts and/or prodrugs thereof, where G, R2, and R3 are defined as described herein.